Aurobindo Pharma Ltd (AUROPHARMA) is listed on the NSE in the Pharmaceuticals sector, Pharmaceuticals & Biotechnology industry. Market capitalisation: 92831.47 Cr. Figures below are as reported and are shown with their source and date.
Aurobindo Pharma Ltd. engages in the manufacturing of generic pharmaceuticals and active pharmaceutical ingredients. The company is headquartered in Hyderabad, Telangana and currently employs 15,690 full-time employees. The firm develops, manufactures and distributes generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients. Its product portfolio is spread over seven therapeutic/product areas encompassing central nervous systems (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-allergic. The company is engaged in developing a range of oncology and hormonal products. The company is developing topical as well as transdermal products in the dermatology therapeutic segment. The company is also developing about three depot injections based on the microsphere and nano-suspension technology platforms. The firm is marketing its products globally in approximately 150 countries. The firm's subsidiaries include APL Healthcare Limited, Auronext Pharma Private Limited, Auro Peptides Limited, APL Pharma Thai Limited and Aurolife Pharma LLC, among others.
Source: finedge · as of 2026-09-29
Last close (₹): 1,610.9
Source: quantro_screener_metrics_job · as of 2026-10-22
Source: quantro_screener_metrics_job · as of 2026-10-23
| Year ended | Revenue (₹ Cr) | PAT (₹ Cr) | EPS (₹) |
|---|---|---|---|
| Mar 2026 | 33,653.08 | 3,504.75 | 60.34 |
| Mar 2025 | 31,723.73 | 3,485.88 | 60.02 |
| Mar 2024 | 29,001.87 | 3,172.97 | 54.15 |
| Mar 2023 | 24,855.38 | 1,927.5 | 32.9 |
| Mar 2022 | 23,455.49 | 2,648.15 | 45.2 |
Source: finedge · as of 2026-07-21
Source: finedge · as of 2026-03-31
Source: quantro_company_profiles · as of 2026-10-23
Source: nse · as of 2026-10-05
Figures computed 2026-10-23.